Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) ADVM Provides Gene Therapy Update - Jefferies

May 5, 2020 6:34 AM
Jefferies analyst Biren Amin reiterated a Buy rating and $657.00 price target on Regeneron Pharma (NASDAQ: REGN) after ADVM provided ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments